503A Compounded
Compounded Injectable Vitamins and IV Solutions
Formulary reviewed by Benn Bluestein-Veyra, M.Sc. Organic Chemistry · Founder, ExaVeyra Sciences
Nine sterile preparations spanning single-entity injectables and multi-constituent infusions, prepared for clinics running an infusion service alongside their core practice.
This is the only category in the catalogue where the same active is routinely stocked in two volumes, and where one entry is supplied in a route other than injection. Both facts change how a room is stocked.
Supply and documentation
- Lead time
- 3 to 5 business days from order to delivery, covering both preparation and transit.
- Coverage
- licensed in 33+ states, with licensure confirmed for your destination before a first order ships
- Testing
- Endotoxin and sterility testing on every sterile batch
- Compounded under USP General Chapters 795, 797 and 800
- FDA-registered, GMP-compliant supplier sourcing, with no gray-market material
- Lot identification and the assigned beyond-use date on every container label
- Documentation package matched to what Tennessee Public Chapter 1016 asks of a supplier: particle counts, lot-specific sterility reporting and a Certificate of Analysis
- Certificates of Analysis are documented and lot-specific, held on file with the tissue bank and the pharmacy for your records.
- Account registration in 24 to 48 hours for licensed clinics and practitioners
- Same-day quotes
- Orders placed with the pharmacy within 24 hours of approval
- A dedicated account manager for each practice
ExaVeyra exists to simplify access to biologics, molecules and medical devices through one point of contact, so a practice runs one account rather than three.
- Every formulary page is checked by a chemist. ExaVeyra was founded by an M.Sc. organic chemist, and specification data is verified against the source catalogue rather than reproduced from a vendor sheet.
- When Tennessee became the first state to write exosome documentation into statute, it asked for particle counts, a viscosity report and a lot-specific Certificate of Analysis. That is the package we already supply against.
- One verified account covers biologics, 503A compounded formulations and devices, with a single account manager rather than a separate vendor relationship for each.
Formulary
Available Formulations
What the pharmacy can prepare. This is not a dosing recommendation, and it does not indicate suitability for any patient.
NAD+ (Nicotinamide Adenine Dinucleotide)
Injectable and Nasal Spray
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 100 mg/mL (10 mL) | 90 days | Max 2 vials |
| 10 mg/0.1 mL (15 mL) Nasal Spray | 30 days | Max 1 unit |
Ascorbic Acid (Vitamin C)
Injectable
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 500 mg/mL injectable. (10 mL) | 90 days | Max 2 vials |
| 500 mg/mL injectable. (30 mL) | 90 days | Max 2 vials |
Methylcobalamin (B12)
Injectable
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 5 mg/mL (10 mL) | 90 days | Max 2 vials |
| 5 mg/mL (30 mL) | 90 days | Max 2 vials |
Vitamin B-Complex (Thiamine / Niacinamide / Riboflavin-5-Phosphate / Pyridoxine)
Injectable
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| (Thiamine 100 mg, Niacinamide 100 mg, Riboflavin-5-Phosphate 2 mg, Pyridoxine 2 mg per mL) (30 mL) | 90 days | Max 2 vials |
Magnesium Chloride
Injectable
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 200 mg/mL (50 mL) | Not specified | Max 2 vials |
Biotin
Injectable
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 10 mg/mL (10 mL) | 90 days | Max 2 vials |
Glutathione
Injectable
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 200 mg/mL (10 mL) | 90 days | Max 2 vials |
| 200 mg/mL (30 mL) | 90 days | Max 2 vials |
Vitamin D3
Injectable
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 50,000 IU/mL (30 mL) | 90 days | Max 2 vials |
Myers' Cocktail
Injectable
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| (Thiamine 10 mg, Niacinamide 10 mg, Pyridoxine 0.2 mg, Riboflavin 20 mg, Calcium Gluconate 0.04 mL, Magnesium Chloride 0.1 mL per mL) (10 mL) | 90 days | Max 2 vials |
| (Thiamine 10 mg, Niacinamide 10 mg, Pyridoxine 0.2 mg, Riboflavin 20 mg, Calcium Gluconate 0.04 mL, Magnesium Chloride 0.1 mL per mL) (30 mL) | 90 days | Max 2 vials |
Single-entity and multi-constituent are different purchases
Most of this category is one active in one vial at one concentration. Two entries are multi-constituent infusions where several vitamins are combined in fixed amounts per millilitre, and the whole combination is the product. Each is compounded and released as a unit with its own lot, which is what makes it a distinct preparation from the single-entity vials.
The constituent amounts for the combinations are stated per millilitre in the catalogue name and reproduced in the table. Those are the figures on the label, and they are the ones to plan against.
Two volumes of the same active
Several actives here are offered in a smaller and a larger vial at identical concentration. That is a stocking decision rather than a clinical one: the larger vial reduces per-visit handling for a clinic with steady volume, the smaller one suits intermittent usage, and both carry the same dating.
Because the concentration is the same across both sizes, moving between them changes only how much sits in the fridge, not what is in it. Clinics frequently order both and settle on one after a quarter of real usage data.
One entry is not an injectable
The category includes a nasal spray presentation alongside the injectable vials. It carries a shorter beyond-use date than anything else here and a tighter per-fill ceiling, so it reorders on its own rhythm.
Do not batch it with the vials
The short-dated nasal presentation reorders on its own line rather than with the injectables. A separate cadence keeps it arriving fresh.
Sterility and cold storage
Everything in this category is a sterile preparation, which is the material difference between it and the topical categories. Each batch undergoes endotoxin and sterility testing before release, and compounding is performed under the sterile chapter rather than the non-sterile one.
Storage follows the container label, and refrigeration requirements are stated per entry rather than per category. Puncture dating applies once a multi-dose vial is entered and is frequently shorter than the beyond-use date on the label, so it is worth building into an infusion room stock rule.
USP General Chapter 797 sets the standards for compounding quality sterile preparations, which is the chapter every preparation in this category is made under. [1]
Under section 503A, a pharmacy compounding for an identified individual patient may use bulk drug substances that comply with an applicable USP or National Formulary monograph where one exists. [2]
Ordering
Accounts are opened to NPI-verified licensed practitioners. Each preparation is dispensed against a prescription for an individual patient, so ordering runs through the pharmacy rather than as stock purchasing, and quantity per fill is bounded by the limits shown for each entry. Wholesale pricing is released once an account is verified.
The shortest limit governs
Assigned beyond-use date, product stability, in-use and puncture dating, the prescribed directions, pharmacy policy and pharmacist review all apply at once, and whichever expires first is the one that counts.
Sources
- USP General Chapter <797>, Pharmaceutical Compounding, Sterile Preparations (accessed 2026-08-09)
- FDA, Section 503A of the Federal Food, Drug, and Cosmetic Act (accessed 2026-08-09)
Verified practitioner access
Request the full formulary and pricing
The pages on this site list a representative selection. Verified practitioners receive the complete named formulary, current wholesale pricing, available strengths and formats, and the identity and credentials of the compounding pharmacy that prepares each preparation.
Access requires a valid NPI. Compounded formulations are prepared by our 503A pharmacy partner, a compounding pharmacy licensed by the Texas State Board of Pharmacy. We verify the number against the national registry before an account is opened, which is why pricing is not published openly: these are prescription preparations supplied to licensed practices rather than consumer products.
Already verified? Sign in to the provider portal
Compounded medications are not FDA-approved finished drug products. Preparations are dispensed against a prescription for a named patient. Nothing on this page is medical advice or a recommendation for any patient.
Equipo de Cumplimiento e Investigación
Hable con Nuestro Equipo de Cumplimiento
Nuestro equipo puede guiarlo a través del contexto de investigación, preguntas sobre el suministro y consideraciones regulatorias. Seleccione las áreas de interés y lo conectaremos con el especialista adecuado.
Áreas de interés marque todas las que correspondan
Todas las consultas son revisadas por nuestro equipo de cumplimiento e investigación. No compartimos su información con terceros.
Frequently asked questions
- Can we combine single-entity vials into our own infusion?
- What a clinic prepares at the point of care is governed by its own policies and applicable rules. What the pharmacy supplies is listed above, prepared and released as discrete lots, each with its own documentation.
- Is the larger vial the same product as the smaller one?
- Same active, same concentration, different volume and a separate lot. It is a stocking choice rather than a different preparation.
- Why does the nasal presentation have such short dating?
- The figure in the table is the beyond-use date the pharmacy assigns for that preparation, and the container label always governs. We can get you the dating rationale for any specific preparation on request.
- Do these require cold-chain shipping?
- Storage requirements are stated per entry on the container label, and they vary across a category spanning single-entity vials, multi-constituent infusions and a nasal presentation. Your account manager can confirm them for the specific items you plan to stock.
- What is the regulatory status of these formulations?
- Compounded medications are not FDA-approved finished drug products. They are prepared under section 503A of the Federal Food, Drug, and Cosmetic Act against a prescription for an individual patient, which is a separate regulatory pathway rather than a lesser version of the same one.
- What documentation ships with an order?
- Lot identification on the container label, with a Certificate of Analysis available on request. Practices with their own documentation requirements should raise them at account setup so the pharmacy can confirm what it is able to supply.
- Who can open an account?
- NPI-verified licensed practitioners. Verification happens before pricing is released, and licensure is confirmed for the destination state before a first order ships.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Compounded medications are not FDA-approved and are prepared by a licensed 503A compounding pharmacy per individual patient prescription. Formulations are supplied to NPI-verified licensed practitioners only. A Certificate of Analysis and lot documentation are available on request. Nothing on this page is medical advice, a dosing recommendation, or a statement that any formulation is suitable for a given patient.
Reviewed 2026-08-09 by Benn Bluestein-Veyra, M.Sc. Organic Chemistry, founder, exaveyra sciences. Specifications on this page are transcribed from the pharmacy formulary and checked line by line against the source catalogue.